Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with high-risk polyps through a colorectal cancer screening programme, a family history-based prevention programme, or you are already being monitored after polyps were previously found — and your situation includes at least one of the following: 10 or more adenomas (a type of polyp); 5 or more serrated polyps in the upper part of the colon; 2 or more serrated polyps that are 10mm or larger; a condition called Serrated Polyposis Syndrome; an early-stage bowel cancer (stage pT1) that was fully removed by endoscopy without needing surgery; a large flat or slightly raised polyp (20mm or more) that was removed in pieces; polyps that were removed but where the edges could not be properly checked, meaning a repeat colonoscopy may be needed; or a very early cancer confined to the inner lining of the bowel (confirm with trial site)
- You regularly consume milk and dairy products
- You are willing and able to sign a consent form agreeing to take part
Who may not be able to join:
- You have had an allergic reaction in the past to substances that are chemically similar to the treatments being studied in this trial (confirm with trial site)
- Your most recent colonoscopy was incomplete or the bowel preparation was considered poor quality (confirm with trial site)
- You regularly take or are likely to need to take aspirin, anti-inflammatory painkillers (such as ibuprofen), misoprostol, steroids, or statins during the study period
- You have had previous surgery on your colon, small intestine, or stomach that could affect how your body absorbs nutrients
- You have a condition called Familial Adenomatous Polyposis (an inherited condition causing large numbers of polyps)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Angel Lanas Arbeloa, MD, PhD, University Hospital Lozano Blesa. IIS Aragón. CIBER de Enfermedades Hepáticas y Digestivas.
Phone: 0034 976 76 57 86
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline levels in pro-inflammatory circulating markers C-reactive protein (CRP), interleukin (IL)-6, macrophage inhibitory cytokine 1 (MIC-1) and tumour necrosis factor alpha (TNFα), as well as in fecal calprotectin.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.